Colloidal iron species driven enhanced H2O2 decomposition into hydroxyl radicals for efficient removal of methylene blue from water.

Colloids are wide-spread in natural waters and colloid-facilitated transport via adsorption was established as the most important mechanism for the mobilization of aqueous contaminants. This study reports another possible, but reasonable, role of colloids for the contaminants driven by redox reactions. Under the same conditions (pH 6.0, 0.3 ml 30% H2O2, and 25 °C), the degradation efficiencies of methylene blue (MB) at 240 min over Fe colloid, Fe ion, Fe oxide and Fe(OH)3 were 95.38%, 42.66%, 4.42% and 9.40%. We suggested that, Fe colloid can promote the H2O2 based in-situ chemical oxidation process (ISCO) compared with other iron species such as Fe(Ⅲ) ion, Fe oxide and Fe(OH)3 in natural water. Furthermore, the MB removal via adsorption by Fe colloid was only 1.74% at 240 min. Hence, the occurrence, behavior and fate of MB in Fe colloid containing natural water system mainly depends on the reduction-oxidation rather than adsorption-desorption process. Based on the mass balance of colloidal iron species and characterization of iron configurations distribution, Fe oligomers were the active and dominant components for Fe colloid-driven enhanced H2O2 activation among three types of Fe species. The quick and steady conversion of Fe(III) to Fe(II) was proven to be reason why Fe colloid can efficiently react with H2O2 to produce hydroxyl radicals.

Entecavir-Associated Thrombocytopenia: A Case Report and Review of the Pathophysiology, Diagnosis, and Treatment of a Rare but Reversible Cause of Thrombocytopenia.

Drug-associated thrombocytopenia is often unrecognized. We report a 76-year-old female with lymphoma who presented with easy bruising and oral bleeding. She had undergone screening for hepatitis B virus (HBV) prior to starting rituximab and was found to have hepatitis B core serum antibody (IgG anti-HBc). She was therefore treated with prophylactic entecavir 0.5 mg daily to prevent reactivation of HBV. Her initial platelet count was 136,000/mm3. Five days after starting entecavir, she presented with bruising and oral bleeding and was found to have a platelet count of 7,000/mm3. A coagulation profile and the rest of the blood parameters (RBC and WBC counts) were normal. Entecavir was stopped, and she was given 3 units of apheresed platelets followed by intravenous immunoglobulin (1 g/kg) for 5 consecutive days. Her platelet counts improved and normalized in one week. She was diagnosed with entecavir-induced thrombocytopenia based on the temporal relationship and after carefully excluding alternate causes of thrombocytopenia. This case highlights the importance of recognizing drug-induced thrombocytopenia (DITP) as a reversible cause of thrombocytopenia.

The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience.

BACKGROUND: Pancreas cancer is highly lethal even at early stages. Adjuvant therapy with chemotherapy (CT) or chemoradiation (CRT) is standard following surgery to delay recurrence and improve survival. There is no consensus on the added value of radiotherapy (RT). We conducted a retrospective analysis of clinical outcomes in pancreas cancer patients treated with CT or CRT following surgery. METHODS: Patients with resected pancreas adenocarcinoma were identified in our institutional database. Relevant clinicopathologic and demographic data were collected. Patients were grouped according to adjuvant treatment: group A: no treatment; group B: CT; group C: CRT. The primary endpoint of overall survival was compared between groups B vs. C. Univariate and multivariate analyses of potential prognostic factors were conducted including all patients. RESULTS: A total of 146 evaluable patients were included (group A: n = 33; group B: n = 45; group C: n = 68). Demographics and pathologic characteristics were comparable. There was no significant survival benefit for CRT compared with CT (mOS 16.8 months vs. 21.5 months, respectively, p = 0.76). Local recurrence rates were similar in all three groups. Univariate analyses identified absence of lymph node involvement (hazards ratio [HR] 1.43, p = 0.0082) and administration of adjuvant therapy (HR 0.496, p = 0.0008) as significant predictors for improved survival. Multivariate analyses suggested that patients without nodal involvement derived the most benefit from adjuvant treatment. CONCLUSIONS: The addition of RT to CT did not improve survival over CT. Lymph node involvement predicts inferior clinical outcome.